Fish Allergy Clinical Trial
Official title:
FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.
The aim of this study is to investigate the safety and tolerability of Subcutaneous
Immunotherapy treatment (SCIT) with incremental doses of a modified recombinant fish
parvalbumin (mCyp c 1) quantified in mass units:
To establish a safe dose of the candidate hypo-allergen in human subjects and To study the
pharmaco-dynamics of the hypo-allergen administered to human subjects.
The study is performed as a placebo-controlled double-blinded randomized trial with 24 fish
allergic patients allocated into three different groups of eight.
The aim of the FAST project in general is to develop novel recombinant allergen-based therapeutics for the treatment of food allergy. The chosen approach is to modify recombinant allergens into hypo-allergenic molecules to decrease the risk of anaphylactic side-effects and to allow administration of higher doses leading to better efficacy. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02365168 -
Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish
|
N/A | |
| Active, not recruiting |
NCT05590299 -
Fish Oral Immunotherapy in Hong Kong Children
|
N/A |